Evidence map›Paper›PMID 24516352›Full record

ArticleInternational journal of medical sciences2014

Comparison of the inhibitory effect of gonadotropin releasing hormone (GnRH) agonist, selective estrogen receptor modulator (SERM), antiprogesterone on myoma cell proliferation in vitro.

Youn-Jee Chung, Boah Chae, Se-Hyun Kwak, Jae-Yen Song, Ah-Won Lee, Hyun-Hee Jo, Young-Ok Lew, Jang-Heub Kim, Mee-Ran Kim

Open access · goldAbstract readComparative Study
In one paragraph

Article in International journal of medical sciences, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 16 citations in OpenAlex.

  1. Advancements and Emerging Therapies in the Medical Management of Uterine Fibroids: A Comprehensive Scoping Review.Medical science monitor : international medical journal of experimental and clinical research · 2024
    Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Youn-Jee Chung1. Department of Obstetrics and Gynecology, The Catholic University of Korea, Republic of Korea.
Boah Chae1. Department of Obstetrics and Gynecology, The Catholic University of Korea, Republic of Korea.
Se-Hyun Kwak1. Department of Obstetrics and Gynecology, The Catholic University of Korea, Republic of Korea.
Jae-Yen Song1. Department of Obstetrics and Gynecology, The Catholic University of Korea, Republic of Korea.
Ah-Won Lee2. Department of Hospital Pathology, The Catholic University of Korea, Republic of Korea.
Hyun-Hee Jo1. Department of Obstetrics and Gynecology, The Catholic University of Korea, Republic of Korea.
Young-Ok Lew1. Department of Obstetrics and Gynecology, The Catholic University of Korea, Republic of Korea.
Jang-Heub Kim1. Department of Obstetrics and Gynecology, The Catholic University of Korea, Republic of Korea.
Mee-Ran Kim1. Department of Obstetrics and Gynecology, The Catholic University of Korea, Republic of Korea.
Catholic University of Korea · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Uterine myomas are the most common gynecologic tumor in women of reproductive age. Treatment options of uterine myomas consist of surgical, medical and interventional therapy such as uterine artery embolization or myolysis. Given that it is the most common type of tumor in women of reproductive age, the treatment of uterine myomas must prioritize uterine conservation. There are several drugs for medical treatment of uterine myoma such as gonadotropin releasing hormone (GnRH) agonist, selective estrogen receptor modulator (SERM) and antiprogesterone. The objective of this study was to compare the effect of GnRH agonist, SERM, and antiprogesterone in the treatment of uterine myomas in vitro. The effect of drugs was evaluated through the cell viability assay in cultured leiomyoma cells, western blot analysis of proliferating cell nuclear antigen (PCNA), and BCL-2 protein expression. As a result, mifepristone single-treated group represents the most significant reduction in myoma cell viability and proliferation. When pretreated with leuprolide acetate, raloxifene shows more significant reduction in myoma cell viability and proliferation than mifepristone. This study suggests one of the possible mechanisms how medications act on uterine myoma, especially at the molecular level.

Indexed as

Antineoplastic Agents, HormonalCell Line, TumorCell ProliferationFemaleGene Expression Regulation, NeoplasticGonadotropin-Releasing HormoneHumansIn Vitro TechniquesLeiomyomaMyomaProgesteroneProliferating Cell Nuclear AntigenProto-Oncogene Proteins c-bcl-2ReproductionSelective Estrogen Receptor ModulatorsUterine NeoplasmsAntineoplastic Agents, HormonalGonadotropin-Releasing HormoneProgesteroneProliferating Cell Nuclear AntigenProto-Oncogene Proteins c-bcl-2Selective Estrogen Receptor ModulatorsDrug therapyGonadotropin-releasing hormone agonistLeiomyomaMifepristoneRaloxifene

Identifiers

PMID24516352
PMCPMC3917117
OpenAlexW2036221791

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.